Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital
RBC Capital maintained a Hold rating on Crispr Therapeutics (CRSP) with a $50 target. UBS also gave a Hold, while Piper Sandler reiterated a Buy. CRSP reported Q2 revenue of $10.18M and a net loss of $91.15M. Insider sentiment is negative, with recent sales by directors.
How this was made
The 30-second read
Why it matters
Analyst holds and insider sales suggest limited upside, but the earnings improvement may soften negative pressure.
Market read
The article provides modest new information—analyst holds and insider sales—offering limited actionable insight for traders.
What to watch
Potential upcoming clinical trial data or partnership announcements not covered in the article.
Background
CRISPR Therapeutics reported Q2 revenue of $10.18 million and a GAAP loss of $91.15 million, a significant improvement from the prior year.
Ticker impact
RBC Capital and UBS maintain Hold ratings with a $50 price target; Piper Sandler reiterates Buy; recent insider sales of 13,679 shares for $780,934.
likely pressure as the market prices in the hold rating and insider sell activity
Hold ratings provide no catalyst, while insider selling signals reduced confidence, which may weigh on the stock.
Market effects
Minimal impact on the broader biotech sector; similar companies may see modest sentiment drift.
No significant regional effect; news is confined to U.S. investors.
Low global relevance; limited to CRSP shareholders.
Counterpoint
Despite the hold ratings, the recent earnings beat and revenue growth could support a short‑term rally.
Key entities
- AnalystLuca Issi
RBC Capital analyst who maintained a Hold rating with a $50 target.
- AnalystJoon Lee
UBS analyst who also maintained a Hold rating.
- DirectorAli Behbahani
CRSP director who sold 13,679 shares.


